Det vi støtter (kun på engelsk)

Funded projects
1,200+
Men's Health Partners
20
Countries
21
"We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact." - Adam Garone, Executive Director, Chief Mo Bro​
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programmes
Mental health and suicide prevention
“We’re alarmed by the increasing number of men who take their own lives around the world. We are working to ensure all men and boys look after their mental health and are comfortable to reach out to others for support when they’re struggling.” Therese Fitzpatrick, Global Mental Health Lead.
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programmes.

GAP2 The Advanced Prostate Cancer Imaging Initiative

Country
Australia
Implemented by
The Movember Foundation
Report Card Date
31 July 2016
Reporting period
January 2014 to July 2016
Project Status
In Progress

AUD 1,035,499

Movember Funding to Date

What we seek to achieve

To improve imaging techniques for men with advanced prostate cancer. By better determining where prostate cancer has spread and what sort of cells make up this spread, treatments can be better tailored for an individual.

How the project works

As part of the Movember Foundation's GAP program, the GAP2 project has brought together leading researchers from around the world to collaborate, share knowledge and together build this groundbreaking project.

The GAP2 Advanced Prostate Cancer Imaging Initiative is made up of 3 distinct sub-projects. Each of these 3 projects is investigating the use of a novel, radioactive PET imaging tracer to investigate the spread of cancer cells in men with advanced disease.  

The three tracers under investigation are called: 

  1. Fluorodihydrotestosterone (FDHT) - a project with contributions from American, British, Australian and Dutch research groups, 
  2. Choline - a project with contributions from Canadian, Australian and British research groups, and 
  3. Prostate Specific Membrane Antigen (PSMA) - a joint American and Canadian research project.
This project will ultimately impact men with advanced disease.  This includes men who have a rising PSA test after surgery to remove their prostate gland and also men who have widespread, castrate-resistant prostate cancer.  These men may have better outcomes if treatments can be more appropriately directed by new imaging tests.

This project has been governed by the Movember GAP2 Project Research Advisory Committee - a global team of highly regarded experts in the field that have guided and shaped the project with the project leaders.

What we are doing / have done

The GAP2 FDHT project is an imaging clinical trial which is currently open and accruing patients.  A total of 105 men with prostate cancer will have FDHT-PET scans at varying timepoints to determine the characteristics of this important and novel tracer.  Some of the men with prostate cancer recruited in the Netherlands, have also had pharmacokinetic tracer modelling - a highly complex analytical study of exactly how this tracer travels through the bloodstream and throughout the body.
 
The GAP2 Choline clinical trial is open and accruing patients from around the world.  The project team will use FCH-PET imaging to determine whether the results of these scans impact on management decisions relating to the use of radiotherapy as a second-line treatment.  The Australian sites involved in this study will also utilise a different prostate imaging agent called 68Ga-PSMA to directly compare which is better at detecting disease.
 
The PSMA project team has developed a reproducible and automated method of manufacturing this second generation tracer and are now testing it in a small number of men with prostate cancer to determine its performance characteristics.  20 men will be recruited to a phase I clinical trial at both McMaster University in Canada and Johns Hopkins University in the USA.
 
All three of these very complex projects have required local and governmental ethics and regulatory approvals across several countries (each with different regulatory requirements) whilst maintaining a common protocol.  All required approvals are now in place and recruitment of study participants is ongoing and expected to be complete by the end of 2016.
 
For a full list of GAP2 Global Prostate Cancer Imaging Initiative funded projects, please click here.
 

Close this report card

For more information on this project or any of the Movember Funded Projects please contact programs@movember.com

>
Page 1 of 19